Neuronetics IncSTIM
Price$2.22

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $155.1M+107.1% YoYTTM through 30 Jun 2026
Net Income -$30.4MTTM through 30 Jun 2026
Free Cash Flow -$11.3MTTM through 30 Jun 2026

Margins

Current
Gross Margin46.9%
EBITDA Margin-12.7%
Operating Margin-26.1%
Net Margin-19.6%

Returns

-280.6%ROE
-29.7%ROA

Balance Sheet Health

Debt / Equity4.89x
Current Ratio1.88x
Net Debt$51.8M
Cash & Equivalents$19.2M

Quality Metrics

Altman Z-Score-2.99
Piotroski F-Score5 / 9
FCF Margin-7.3%
Rule of 40-3.4
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $149.2M
Diluted EPS-$0.43TTM
'19'20'21'22'23'24'25
FY2025: $-0.59

Dividend

No dividend

Capital Allocation

R&D Spend$5.9M
Capex Intensity0.6%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.